Skip to main content

Day: March 31, 2026

BIO-key Reports 2025 Results and Substantially Improved Cash Position, Supporting Expected Strong Growth in 2026; Investor Call Today at 10am ET

HOLMDEL, N.J., March 31, 2026 (GLOBE NEWSWIRE) — BIO-key® International, Inc. (Nasdaq: BKYI), a global leader in Identity and Access Management (IAM) and biometric authentication technologies, announced its fourth quarter (Q4’25) and year ended December 31, 2025 (2025) results. BIO-key will host an investor call today at 10:00am ET (details below). Highlights:  •   2025 Revenue:   $6.1M  •   2026 Outlook:   Solid revenue growth + improved bottom line  •   Preliminary Q1’26 Revenue:   $2.2M, up 37% vs. Q1’25 and 80% vs. Q4’25  •   2025 Cash Position:   $2.7M, up $2.3M vs. $0.4M vs. 2024BIO-key CEO, Mike DePasquale commented, “We had a broad base of achievements in 2025, the revenue and bottom-line benefits of which will be realized in early 2026 and beyond. In 2025, we completed our strategic transition to selling...

Continue reading

KOIL Energy Reports Fourth Quarter and Full Year 2025 Results

– Revenue of $7.3 million, 22% growth – Gross margin of 35% – Adjusted EBITDA margin of 10% HOUSTON, March 31, 2026 (GLOBE NEWSWIRE) — KOIL Energy Solutions, Inc. (OTCQB: KLNG), a specialist in deepwater energy production and distribution equipment and services, released today its fourth quarter and full year 2025 results. “We achieved a record revenue of $7.3 million this quarter,” said Erik Wiik, President and Chief Executive Officer of KOIL Energy. “Our growth initiatives are delivering profitable growth with an EBITDA margin of 10% while we continue to invest heavily in growth.” Fourth Quarter 2025 Results: For the three months ending December 31, 2025, KOIL Energy generated revenues of $7.3 million dollars. This is 22% higher than Q4 last year and 14% higher than last quarter. Both...

Continue reading

Volatus Aerospace Reports Fiscal Year 2025 Financial Results

Revenue Growth of 26% year-over-year Defence Equipment revenues more than 2x from 2024 Total Assets of C$92M+, up ~60% year-over-year Europe & UK revenue grew 150%, driven by NATO-aligned defence business Current cash balance of ~C$41M Secured a NATO defence contract valued at up to C$9M in Dec 2025 Establishment of the Volatus Innovation & Drone Manufacturing Facility in Mirabel, QCMONTREAL, March 31, 2026 (GLOBE NEWSWIRE) — Volatus Aerospace Inc. (TSX: FLT) (OTCQX: TAKOF) (Frankfurt: ABB.F) (“Volatus” or the “Company”), a Canadian-controlled global aerospace and defence company delivering integrated uncrewed systems, aerial intelligence, and mission-critical operational services, today released its audited consolidated financial results for the fiscal year ended December 31, 2025. Fiscal 2025 was the Company’s first...

Continue reading

AlphaGen Announces Definitive Agreement to Acquire Quantum Vision Holdings Inc.

Transaction will represent a Fundamental Change of AlphaGen VANCOUVER, British Columbia, March 31, 2026 (GLOBE NEWSWIRE) — AlphaGen Intelligence Corp. (CSE: AIC) (FSE: G4G) (“AlphaGen” or, the “Company”) is pleased to announce that it has entered into a definitive share exchange agreement (the “Agreement“) with Quantum Vision Holdings Inc. (“Quantum Vision“) pursuant to which AlphaGen will acquire all of the issued and outstanding shares of Quantum Vision (the “Transaction“). The Transaction will constitute a “Fundamental Change” of AlphaGen under the policies of the Canadian Securities Exchange (the “CSE“). Subject to satisfaction or waiver of all conditions precedent to the Transaction, AlphaGen anticipates that the Transaction will be completed no later than...

Continue reading

Skeena Gold & Silver Confirms Eskay Creek Reaches 49% Completion & Provides Project Update; Initial Production Remains on Schedule for Q2 2027

VANCOUVER, British Columbia, March 31, 2026 (GLOBE NEWSWIRE) — Skeena Resources Limited (TSX: SKE, NYSE: SKE) (“Skeena Gold & Silver”, “Skeena” or the “Company”) is pleased to provide an update on the advancement of its 100% owned Eskay Creek Gold-Silver Project (“Eskay” or the “Project”) in Northwest British Columbia. Since commencing development activities in December 2024, the Company has achieved notable progress advancing Eskay Creek. As of February 28, 2026, the Project was 49% complete, with 66% of total project costs now contractually committed. Initial production at Eskay Creek remains on schedule, targeted for the second quarter of 2027 and commercial production expected in the third quarter. Randy Reichert, President & Chief Executive Officer of Skeena, commented, “Our strategy of initiating development activities...

Continue reading

MAAS Completes Strategic Acquisition of Huazhi Future, Establishing Full-Stack AI Self-Controllability

QINGDAO, China, March 31, 2026 (GLOBE NEWSWIRE) — Maase Inc. (NASDAQ: MAAS) (“MAAS” or the “Company”) today announced the successful completion of its acquisition of 100% equity interests in Times Good Limited, which in turn controls the core assets and operations of Huazhi Future (Chongqing) Technology Co., Ltd. and its subsidiaries (collectively, the “Huazhi Group”). The transaction, previously disclosed on January 23, 2026, was consummated on March 30, 2026. The successful completion of this acquisition marks MAAS’s strategic evolution from a “Scenario Operator” to an “AI Industry Player” with full-stack, self-controlled capabilities. As of March 30, 2026, the Company had a total of 442,175,578 ordinary shares outstanding, consisting of 435,508,910 Class A ordinary shares and 6,666,668 Class B ordinary shares. The sellers collectively...

Continue reading

Form 8.3 – BRCK Group plc – Octopus Investments

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)        Full name of discloser: OCTOPUS INVESTMENTS LTD(b)        Owner or controller of interests and short positions disclosed, if different from 1(a):         The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.  (c)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree BRCK GROUP PLC(d)        If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  (e)        Date position held/dealing undertaken:...

Continue reading

Ormat Technologies, Inc. to Host Conference Call Announcing First Quarter 2026 Financial Results

RENO, Nev., March 31, 2026 (GLOBE NEWSWIRE) — Ormat Technologies Inc. (NYSE: ORA) (the “Company” or “Ormat”), a leading geothermal and renewable energy company, today announced that it plans to publish its first quarter financial results in a press release that will be issued on Wednesday, May 6, 2026, after the market closes. In conjunction with this report, the Company has scheduled a conference call to discuss the results at 09:00 a.m. ET on Thursday May 7, 2026. Participants within the United States and Canada, please dial 1-800-715-9871, approximately 15 minutes prior to the scheduled start of the call. If you are calling from outside the United States or Canada, please dial +1-646-307-1963. The access code for the call is 3818407. Please request the “Ormat Technologies, Inc. call” when prompted by the conference call operator....

Continue reading

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting

Fort Lee, NJ, March 31, 2026 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced upcoming presentations for NXP900 at the upcoming 2026 American Association for Cancer Research Meeting (2026 AACR), taking place from April 17th to April 22nd in San Diego, CA.Abstract Title Poster Presentation DetailsNXP900, a Phase 1b, first-in-class YES1/SRC inhibitor demonstrates potent synergy with KRAS inhibitors in KRASi sensitive and resistant NSCLC models Session TitleCombination Targeted Therapy Session Date / TimeApril 21st, 2:00 PM – 5:00 PM PTResistance to the SFK inhibitor NXP900...

Continue reading

Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update

NORCROSS, Ga., March 31, 2026 (GLOBE NEWSWIRE) — Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2025. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said “We are at an important juncture for the belapectin development program. During 2025, we made meaningful progress advancing the belapectin program and continuing our analysis of the NAVIGATE dataset in patients with MASH cirrhosis and portal hypertension. We are encouraged by the signals observed, including additional biomarkers from the NAVIGATE dataset, and remain focused on evaluating the data as we engage with regulators, potential partners, and leading experts to determine the optimal...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.